Add to a list

Inactive Instrument

genOway SA Stock Xetra

JEH

FR0004053510

Biotechnology & Medical Research

OTC Markets Traded

End-of-day quote Xetra Other stock markets
- ^EUR	-

03-30	GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-30	GenOway Société anonyme completed the acquisition of Data Science and AI assets in OMICS platform.	CI

Analysts' recommendations: genOway SA

23-11-22	GenOway: sharp rise, broker initiates buy recommendation
23-11-22	GenOway: Euroland initiates buy coverage

More recommendations

News in other languages: genOway SA

07-15	Genoway dégage 10,9 MEUR de revenus au 1er semestre 2026
07-15	Genoway : Revenus totaux de 10,9 M EUR au 1er semestre 2026 - Accélération de la croissance visée au 2nd semestre
07-02	GenOway : 20260630 Bilan semestriel du contrat de liquidité - Juin 2026
06-19	Agenda des dividendes et des AG de la semaine : session dividendes pour la galaxie Bolloré
06-03	GenOway : 20260626 Avis de convocation

More news

Managers and Directors: genOway SA

Manager	Title	Age	Since
Christian Grenier CEO	Chief Executive Officer	-	-
Alexandre Fraichard COO	Chief Operating Officer	-	1999-02-28
Benjamin Bruneau DFI	Director of Finance/CFO	-	2015-09-30

Director	Title	Age	Since
Alexandre Fraichard BRD	Director/Board Member	-	1999-02-28
Christian Grenier CHM	Chairman	-	-
Laurent Fraisse BRD	Director/Board Member	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+0.93%	-0.63%	+3.89%	+14.93%	48.57B
REVOLUTION MEDICINES, INC.	+0.26%	+2.93%	+439.43%	+533.80%	41.95B
IQVIA HOLDINGS INC.	-1.53%	-2.25%	+30.95%	+7.15%	38.85B
BEONE MEDICINES AG	+0.69%	+2.40%	+10.48%	+63.05%	37.24B
CELLTRION, INC.	+2.47%	+2.63%	+14.71%	+48.37%	30.67B
MEDPACE HOLDINGS, INC.	-0.47%	+1.16%	+35.93%	+126.09%	16.41B
ASCENDIS PHARMA A/S	+2.31%	-0.49%	-	-	16.1B
EUROFINS SCIENTIFIC SE	+0.29%	+1.87%	+8.17%	+18.60%	13.97B
ICON PUBLIC LIMITED COMPANY	-1.43%	-2.63%	+3.70%	-36.38%	12.62B
Average	+0.39%	+0.30%	+68.41%	+96.95%	28.48B
Weighted average by Cap.	+0.44%	+0.23%	+89.13%	+121.09%

See all sector performances

genOway est une société de biotechnologie spécialisée dans la conception et le développement de modèles de recherche moléculaires, cellulaires et animaux à forte valeur ajoutée pour les industries biopharmaceutique, chimique, agrochimique et agroalimentaire ainsi que pour la recherche académique. genOway est une société leader sur son marché. Elle appuie son développement sur la combinaison d'une large et exclusive plateforme technologique et d'une propriété intellectuelle forte combinant brevets et licences d'exploitation. genOway a conclu de nombreux contrats commerciaux avec les leaders de l'industrie pharmaceutique (BMS, Janssen, Novartis, Pfizer, etc.), et avec les centres de recherche académiques les plus prestigieux (King's College et Université de Manchester en Angleterre, Harvard, Caltech et le National Institute of Health aux Etats-Unis, l'Institut Pasteur en France, le NGFN et l'Institut Max Planck en Allemagne, etc.).

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	23.05M 26.56M 21.58M 19.74M 37.27M 2.53B 37.76M 253M 99.1M 1.26B 99.73M 97.56M 4.21B	P/E 2024 *	-	P/E 2025	-
Enterprise Value	29.77M 34.3M 27.87M 25.5M 48.14M 3.27B 48.77M 326M 128M 1.63B 129M 126M 5.43B	EV / Sales 2024	1.28x	EV / Sales 2025	1.11x
Free-Float	59.02%	Yield 2024 *	-	Yield 2025	-

03-30	GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-30	GenOway Société anonyme completed the acquisition of Data Science and AI assets in OMICS platform.	CI
12-15	GenOway Société anonyme agreed to acquire Data Science and AI assets in OMICS platform for ?7 million.	CI
11-19	GenOway Soars 18% on Strong Momentum from Chinese Joint Venture
25-09-24	GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-03-27	GenOway Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-09-23	GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-19	GenOway: 15% growth in first-half sales
23-11-22	GenOway: sharp rise, broker initiates buy recommendation
23-11-22	GenOway: Euroland initiates buy coverage
23-10-17	GenOway: creation of a joint venture in Shanghai
23-09-22	GenOway: profitability target achieved ahead of schedule
23-09-20	GenOway Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI

03-16	GenOway : 20250627 Avis de convocation	PU
11-18	Accélération du développement en Chine : la coentreprise genOway Shanghai devient un moteur clé de croissance pour le Groupe	PU
25-09-22	GenOway : Solides résultats semestriels 2025 avec une marge d’EBITDA à 16,9%	PU
24-03-27	GenOway : Résultats annuels 2023	PU
23-09-22	GenOway : Résultats du 1er semestre 2023	PU

	2024	2025
Net sales	27.53M 31.73M 25.78M 23.58M 44.52M 3.02B 45.1M 302M 118M 1.51B 119M 117M 5.03B	28.6M 32.96M 26.78M 24.5M 46.25M 3.14B 46.85M 313M 123M 1.57B 124M 121M 5.22B
Net income	1.83M 2.11M 1.71M 1.57M 2.96M 201M 3M 20.06M 7.87M 100M 7.92M 7.75M 334M	928K 1.07M 869K 795K 1.5M 102M 1.52M 10.16M 3.99M 50.88M 4.01M 3.93M 169M
Net Debt	623K 718K 583K 534K 1.01M 68.38M 1.02M 6.82M 2.68M 34.17M 2.7M 2.64M 114M	6.72M 7.74M 6.29M 5.75M 10.86M 737M 11.01M 73.6M 28.88M 368M 29.07M 28.43M 1.23B

genOway SA Stock Xetra

Stocks

JEH

FR0004053510

Biotechnology & Medical Research

Valuation: genOway SA

Latest news : genOway SA

Analysts' recommendations: genOway SA

Press Releases: genOway SA

News in other languages: genOway SA

Managers and Directors: genOway SA

Other Biotechnology & Medical Research

Financials

Company Profile